Trial Profile
A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Diffuse large B cell lymphoma; Myelofibrosis
- Focus Adverse reactions; Proof of concept
- Acronyms KEYNOTE145
- Sponsors Acerta Pharma
- 19 Jan 2024 Planned End Date changed from 31 Dec 2025 to 1 Apr 2026.
- 08 Mar 2021 Planned End Date changed from 1 May 2021 to 31 Dec 2025.
- 18 Sep 2019 Planned End Date changed from 1 Apr 2021 to 1 May 2021.